Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver diseaseTeruki Miyake, Yoichi Hiasa, Sakiko Yoshida et al.|Open Medicine|2018Cited by 48
Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteriaHironori Ochi, Kouji Joko, Atsushi Hiraoka et al.|Journal of Gastroenterology|2020Cited by 45
Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factorKanako Konishi, Yoichi Hiasa, Teruki Miyake et al.|Atherosclerosis|2020Cited by 43
Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinomaYohei Koizumi, Yoichi Hiasa, Masashi Hirooka et al.|Endocrine Journal|2019Cited by 39
Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinomaAtsushi Yukimoto, Yoichi Hiasa, Masashi Hirooka et al.|Japanese Journal of Clinical Oncology|2018Cited by 35